Trial Profile
Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Anaplastic large cell lymphoma; Diffuse large B cell lymphoma; Haematological malignancies; Hodgkin's disease; Neuroblastoma; Non-Hodgkin's lymphoma; Sarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 08 Mar 2024 This trial has been completed in Italy, as per European Clinical Trials Database record.
- 21 Feb 2024 Planned End Date changed from 29 Dec 2023 to 30 Dec 2024.
- 25 Aug 2023 Planned End Date changed from 28 Feb 2023 to 29 Dec 2023.